chartexchange

Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131

GlobeNewswire Inc. | Oct 27, 2026 7:15 AM EDT

Durable Complete Response Achieved with Single Administration of Iopofosine I 131 

Read original article